<DOC>
	<DOCNO>NCT00589563</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus , sirolimus , antithymocyte globulin , methotrexate transplant may stop happen . PURPOSE : This phase II trial study well sirolimus , tacrolimus , antithymocyte globulin work prevent graft-versus-host disease patient undergo donor stem cell transplant hematological cancer .</brief_summary>
	<brief_title>Sirolimus , Tacrolimus , Antithymocyte Globulin Preventing Graft-Versus-Host Disease Patients Undergoing Donor Stem Cell Transplant For Hematological Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine incidence severity acute- chronic-graft-versus-host disease ( GVHD ) HLA-matched -mismatched unrelated donor hematopoietic peripheral blood transplantation patient hematologic malignancy schedule receive immunosuppressive combination sirolimus , tacrolimus , anti-thymocyte globulin GVHD prophylaxis . - To determine safety combination first six month post-transplant . Secondary - To determine time-to-engraftment , non-relapse mortality rate , overall disease-free survival , incidence disease relapse , incidence opportunistic infection GVHD prophylaxis . OUTLINE : Patients stratify accord condition regimen ( fludarabine phosphate melphalan v fractionate total-body irradiation [ FTBI ] etoposide vs FTBI cyclophosphamide ) degree donor/recipient HLA mismatch ( high-risk v low-risk ) . - Conditioning regimen : Patients receive 1 3 standard conditioning regimen begin day -9 -8 continue day -1 0 . - Peripheral blood stem cell transplantation : Patients receive HLA-matched mismatch unrelated donor peripheral blood stem cell day 0 . - Graft-versus-host disease prophylaxis : Patients receive tacrolimus IV continuously begin day -3 orally tolerate , oral sirolimus day -3 -2 , anti-thymocyte globulin IV 4-8 hour day -3 0 , methotrexate* IV day 1 , 3 , 6 . Tacrolimus sirolimus continue 3-6 month ( taper ) . NOTE : *Only patient high-risk HLA mismatch receive treatment methotrexate . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematological malignancy include follow : NonHodgkin lymphoma ( NHL ) complete remission ( CR ) partial response ( PR ) Hodgkin lymphoma CR PR Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) CR Bone marrow blast &lt; 20 % within 4 week transplant peripheral blood absolute blast count &lt; 500/µL day initiation conditioning patient nonCR AML ALL Myelodysplastic syndrome ( MDS ) treat untreated Chronic myelogenous leukemia ( CML ) chronic accelerate phase Multiple myeloma CR PR Chronic lymphocytic leukemia CR PR 2 great Myelofibrosis myeloproliferative disorder Bone marrow blast &lt; 20 % within 4 week transplant peripheral blood absolute blast count &lt; 500/µL day initiation Highrisk disease define AML ALL &gt; CR1 , accelerate phase CML , recurrent aggressive lymphoma , active lymphoproliferative disease transplant Lowrisk disease define AML ALL CR1 , chronic phase CML , lowgrade lymphoproliferative disorder control disease transplant Must planning receive 1 follow conditioning regimen City Hope : Fludarabine phosphate melphalan patient hematological malignancy contraindication conventional myeloablative regimen due age , comorbidity , previous transplant Fractionated totalbody irradiation ( FTBI ) etoposide patient AML ALL CML accelerate phase FTBI cyclophosphamide patient NHL , AML , CML , MDS Suitable unrelated donor available HLAmatched mismatch Peripheral blood stem cell available No bone marrow ex vivoengineered process graft ( e.g. , CD34positive , Tcell depletion ) No uncontrolled CNS disease PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 70100 % ECOG PS 02 Creatinine &lt; 1.3 mg/dL creatinine clearance ≥ 70 mL/min Ejection fraction &gt; 45 % Direct bilirubin &lt; 3 time upper limit normal ( ULN ) ALT AST &lt; 3 time ULN Forced vital capacity , FEV1 , DLCO &gt; 45 % predict Able cooperate oral medication intake No active donor recipient serology positive HIV No known contraindication administration sirolimus , tacrolimus , antithymocyte globulin No active hepatitis B C Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics Concurrent participation clinical trial prevention treatment viral , bacterial , fungal disease allow provided agent interact agent use current study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>infection</keyword>
	<keyword>adult favorable prognosis Hodgkin lymphoma</keyword>
	<keyword>adult unfavorable prognosis Hodgkin lymphoma</keyword>
	<keyword>childhood favorable prognosis Hodgkin lymphoma</keyword>
	<keyword>childhood unfavorable prognosis Hodgkin lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade I lymphomatoid granulomatosis</keyword>
	<keyword>recurrent grade II lymphomatoid granulomatosis</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>secondary myelofibrosis</keyword>
</DOC>